Sorry, you need to enable JavaScript to visit this website.

Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl alcohol), Due To The Potential Presence of Visible Particulates

Share

FOR IMMEDIATE RELEASE -NEW YORK, NY., August 22, 2022
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Propofol Injectable Emulsion (containing benzyl alcohol),
100mL Single Patient Use Glass Fliptop Vial; lot EA7470, to the user level due to visible particulates observed in two vials during annual examination of retention samples.

Risk Statement: Patients receiving the impacted product have a remote probability of experiencing potential adverse events, such as blockage of blood vessels, including decreased blood flow to the brain, heart attack, pulmonary embolus, and tissue necrosis. Hypersensitivity reactions and transmission of infectious disease can also occur.

To date, Pfizer has not received reports of any adverse events associated with this issue for this lot.

Propofol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Propofol Injectable Emulsion is a terminally sterilized (TS) product. It is a sterile, nonpyrogenic emulsion containing 10 mg/mL of propofol suitable for intravenous administration supplied in a Single Patient Use Glass Fliptop Vial.

The NDC, Lot Number, Expiration Date, and Configuration details for Propofol Injectable Emulsion are indicated below. The product lot was distributed nationwide to wholesalers/hospitals in the United States from July 16, 2020 through July 24, 2020.

ProductNDCLot NumberExpiration DatePresentationConfiguration/ Count
Propofol Injectable Emulsion,
100 mL Single Patient Use Glass
Fliptop Vial
 

Vial:

0409-4699-54

Tray:

0409-4699-24

EA747001 JUNE 20231g/100 mL, Single Patient Use Glass
Fliptop Vial
Tray of 10 Units


Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified direct consignees by letter to arrange for return of any recalled product.

Wholesalers or hospitals with an existing inventory of the lot, which is being recalled, should discontinue use, stop distribution and quarantine immediately. If you have further distributed the recalled product, please notify your accounts and/or any additional locations which may have received the recalled product. Hospitals/Institutions should inform Healthcare Professionals in your organization of this recall. For additional assistance, call Sedgwick Inc. at 1-800-805-3093 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.

Healthcare Professionals with questions regarding this recall can contact Pfizer using the below information.

Contact CenterContact InformationArea of Support
Pfizer Medical Information1-800-438-1985, option 3 (8am to 9pm ET Monday through Friday)  www.pfizermedinfo.comFor medical questions regarding the product
Pfizer Drug Safety1-800-438-1985, option 1 (24 hours a day; 7 days a week)To report adverse events and product complaints


Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being executed with the knowledge of the U.S. Food and Drug Administration.

# # # # #

PROPOFOL Injectable Emulsion, USP (contains benzyl alcohol)
100 mL Single Patient Use, Glass Fliptop Vial

Propofol


Media Contact:
Media Relations
+1-212-733-7410
[email protected]